Epidemiologic studies have shown that low
vitamin D levels are associated with reduced
insulin sensitivity and increased risk of developing
type 2 diabetes mellitus (T2DM). However, there is little evidence that
vitamin D supplementation improves
glucose intolerance. We evaluated the
glucose-lowering effect of
vitamin D in Korean T2DM subjects. We enrolled 158 T2DM patients who had stable
glycemic control [
hemoglobin A1c (HbA1c) <8.5%] and
vitamin D levels less than 20 ng/mL. The participants were randomized into two groups: Placebo (100 mg daily of elemental
calcium administered twice a day) or
Vitamin D (1000 IU daily of
cholecalciferol combined with 100 mg of elemental
calcium administered twice a day). We compared outdoor physical activity,
glycemic control, homeostasis model of assessment -
insulin resistance (HOMA-IR), and
parathyroid hormone (PTH), during the 24-week intervention. We analyzed the data of 129 participants (placebo =65,
vitamin D =64) who completely followed the protocol. Outdoor physical activity and oral anti-diabetic drugs did not differ between the groups. While there were significant differences in the
vitamin D levels (15.6 ± 7.1 ng/mL vs 30.2 ± 10.8 ng/mL, P<0.001) and change in PTH levels (1.4 ± 15.3 pg/mL vs -5.5 ± 9.8 pg/mL, P=0.003) between the placebo and
vitamin D groups, there were no differences in HbA1c (7.27 ± 0.87% vs 7.40 ± 0.90%) (P=0.415) and HOMA-IR. Serum
calcium and kidney function results showed that the
vitamin D supplementation was safe. While
vitamin D supplementation is safe and effective in the attainment of
vitamin D sufficiency, it had no effect on long-term
glycemic control for T2DM in our study.